Patient Persectives Highlight Importance of Modest ALS Treatment Gains
Recent pieces published in the international neurology journal, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, have sparked debate in the ALS community.
In ALS Action Canada’s paper (Darke and Orsulak 2025), “How Effective Does a New Drug for Amyotrophic Lateral Sclerosis Need To Be – The Patient Perspective”, we argued against the proposal of Boddy et al (2025).